NASDAQ
28.65USD
+0.12 (+0.42%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.6B
P/E
—
EPS
—
Beta
2.14
52W range
12.81-53.65
Day range
27.45–28.99
Open
28.95
Prev close
28.53
Volume
480.7K
Avg volume
584K
Dividend
0.00
IPO
2025-01-31
https://www.zacks.com/stock/news/2957228/can-maze-therapeutics-inc-maze-climb-120-48-to-reach-the-level-wall-street-analysts-expect?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2957228 · 7/21/2026+0.80
https://www.globenewswire.com/news-release/2026/04/22/3278633/0/en/Maze-Therapeutics-Announces-150-Million-Registered-Offering.html · 4/22/2026+0.40
https://www.fool.com/coverage/filings/2026/04/04/maze-therapeutics-chief-medical-officer-sold-100-of-his-direct-holdings-here-s-what-this-means-for-investors/ · 4/4/2026-0.65
https://www.zacks.com/stock/news/2890799/after-plunging-30-8-in-4-weeks-here-s-why-the-trend-might-reverse-for-maze-therapeutics-inc-maze?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|rsi-2890799 · 3/27/2026+0.60
https://www.fool.com/coverage/filings/2026/03/21/maze-therapeutics-president-sells-all-insider-shares-as-q4-earning-report-nears/ · 3/22/2026-0.60
https://www.defenseworld.net/2026/01/02/atul-dandekar-sells-72400-shares-of-maze-therapeutics-nasdaqmaze-stock.html · 1/2/2026-0.20
https://www.defenseworld.net/2026/01/02/harold-bernstein-sells-45000-shares-of-maze-therapeutics-nasdaqmaze-stock.html · 1/2/2026-0.20
https://www.cnbc.com/2025/10/28/san-francisco-is-making-a-comeback-so-are-these-stocks-from-the-city-by-the-bay.html · 10/28/2025+0.60
https://www.marketbeat.com/stock-ideas/biotech-breakouts-3-stocks-with-massive-upside-potential/ · 9/17/2025+0.70
https://www.globenewswire.com/news-release/2025/08/12/3132101/0/en/Maze-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Highlights.html · 8/12/2025+0.60
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
